Table 3.
Characteristics of individual studies on TOLLIP variants included in the meta-analysis of survival
| References | Year | Country | Ethnicity | Disease | n | HR | 95% CI | |
|---|---|---|---|---|---|---|---|---|
| rs5743890 | ||||||||
| Associations with transplant-free survival | ||||||||
| Francesco Bonella16 | 2021 | Germany | European | IPF | 37 | 2.22 | 1.15 | 4.29 |
| Chad A. Newton-120 | 2019 | America | European | IPF | 499 | 1.41 | 1.10 | 1.81 |
| Chad A. Newton-220 | 2019 | America | European | IPAF | 233 | 0.65 | 0.37 | 1.13 |
| Chad A. Newton-320 | 2019 | America | European | CTD-ILD | 241 | 0.90 | 0.45 | 1.83 |
| Brett Ley-117 | 2017 | America | European | CHP/IPF | 142 | 0.94 | 0.42 | 2.10 |
| Brett Ley-217 | 2017 | America | European | CHP/IPF | 72 | 0.85 | 0.40 | 1.82 |
| Associations with survival | ||||||||
| Chad A. Newton-120 | 2019 | America | European | IPF | 499 | 1.46 | 1.08 | 1.98 |
| Chad A. Newton-220 | 2019 | America | European | IPAF | 233 | 0.64 | 0.34 | 1.23 |
| Chad A. Newton-320 | 2019 | America | European | CTD-ILD | 241 | 0.80 | 0.36 | 1.77 |
| Brett Ley-117 | 2017 | America | European | CHP/IPF | 142 | 0.91 | 0.39 | 2.14 |
| Brett Ley-217 | 2017 | America | European | CHP/IPF | 72 | 0.78 | 0.27 | 2.26 |
| rs3750920 | ||||||||
| Associations with survival | ||||||||
| Francesco Bonella16 | 2021 | Germany | European | IPF | 37 | 0.77 | 0.33 | 1.84 |
| Takuma Isshiki9 | 2021 | Japan | Asian | FILD | 102 | 0.95 | 0.61 | 1.49 |
| rs111521887 | ||||||||
| Associations with survival | ||||||||
| Patrícia Caetano Mota-125 | 2022 | Portuguese | European | IPF | 21 | 1.65 | 0.83 | 3.26 |
| Patrícia Caetano Mota-225 | 2022 | Portuguese | European | IPF | 2 | 5.99 | 0.74 | 48.20 |
CTD-ILD, connective tissue disease associated interstitial lung diseases; IPAF: Interstitial pneumonitis with autoimmune features; IPF: idiopathic pulmonary fibrosis; CHP: chronic hypersensitivity pneumonitis; FILD: fibrosing ILD